WHO ICTRP trial
Phase Ib study of 131I-metaiodobenzylguanidine(MIBG) therapy with Valproic…
JPRN-UMIN000012032 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000012032 |
|---|---|
| Public title | Phase Ib study of 131I-metaiodobenzylguanidine(MIBG) therapy with Valproic Acid(VPA) for high risk or recurrent neuroblastoma |
| Scientific title | Phase Ib study of 131I-metaiodobenzylguanidine(MIBG) therapy with Valproic Acid(VPA) for high risk or recurrent neuroblastoma - Phase Ib study of VPA and 131I-MIBG for recurrent / resistant neuroblastoma |
| Primary sponsor | National Cancer Research Center Hospital |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase I |
| Countries | Japan |
| Conditions | Intractable neuroblastoma |
| Interventions | (1) After enrollment, starting valproic acid (VPA) and adjusting VPA dosing to reach and keep the target concentration (100ug/ml). (2) Preparing for 131I-MIBG administration by assessing disease status (123I-MIBG, Bone marrow biopsy etc.)… |
| Registration date | Oct 14, 2013 |
| Target size | 10 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: